Abstract: Disclosed is an integrated circuit, system or architecture suitable for NFC functionality and including an NFC companion block connectible to a power source and capable to providing a non-continuous power boost to NFC signals, inter alia, thereby facilitating use of a broader range of antennas, multiple antennas, and thereby providing greater NFC functionality and versatility Further disclosed is a detachable antenna embedded in a potentially detachable shell which closely fits a mobile device and is adapted for use with the above mentioned integrated circuit, system or architecture.

Abstract: Systems and methods provide a mechanism to create and maintain web pages and other types of output pages. The system and methods use an author markup language (AML) to define output pages. Additionally, a Component Markup Language (CML) may be used to define components that may be referenced by the AML. The AML and CML may be translated to an intermediate format, which may then be further processed at runtime to combine dynamic data with the intermediate format to produce the output page.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: A method includes detecting a touch at a plurality of touch locations on a touch-sensitive display of an electronic device, identifying when the touch is a first gesture type based on touch attributes including a first touch location of the plurality of touch locations, and at least one of speed of the touch, time between detecting the touch at consecutive ones of the touch locations, distance between the consecutive ones of the touch locations, and direction of the touch.

Abstract: Systems and methods provide a mechanism to create and maintain web pages and other types of output pages. The system and methods use an author markup language (AML) to define output pages. Additionally, a Component Markup Language (CML) may be used to define components that may be referenced by the AML. The AML and CML may be translated to an intermediate format, which may then be further processed at runtime to combine dynamic data with the intermediate format to produce the output page.

Abstract: A system and method for sample rate adaption. The system and method provide for information derived from sampling at a first rate to be applied or processed at a second rate where the first and second rates differ in frequency and phase. The information is adapted from the first rate to the second rate. Then phase differences including phase introduced as by-product of adapting the frequencies are reduced by phase adaption.

Abstract: A mechanism for fixing together first and second parts and comprising first and second guides provided respectively in or attached to the first and second parts. The mechanism further comprises first and second magnetic components coupled respectively to the first and second guides such that the first magnetic component is rotatable with the first guide and the first part, and the second magnetic component cannot rotate relative to the second guide, the magnetic components being moveable axially and rotationally with respect to each other and having magnetic poles oriented such that rotation of said first magnetic component causes relative axial movement of the magnetic components between a locking position in which one of the magnetic components straddles the two guides and an unlocking position in which it does not straddle the two guides.

Abstract: A mechanism comprising a first component having a first magnetic part, a second component, and a third component having a second magnetic part, the third component being moveable relative to said first component in a given direction to effect connection and or disconnection of the first and second components by causing interaction of the first and second magnetic parts, wherein, when connected, the first and second components are able to move relative to one another in said given direction.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: Disclosed is an integrated circuit, system or architecture suitable for NFC functionality and including an NFC companion block connectible to a power source and capable to providing a non-continuous power boost to NFC signals, inter alia, thereby facilitating use of a broader range of antennas, multiple antennas, and thereby providing greater NFC functionality and versatility Further disclosed is a detachable antenna embedded in a potentially detachable shell which closely fits a mobile device and is adapted for use with the above mentioned integrated circuit, system or architecture.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Abstract: An oral device (2) is designed to be worn in the mouth by a person and to stress the trigeminal nerve during swallowing. A method of learning the performance of an action, which includes the wearing of an oral device (2) by a person in order to stress the trigeminal nerve during swallowing.

Abstract: The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Abstract: The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.